EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+12.44%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.31B
AUM Growth
+$1.31B
(+3.9%)
Cap. Flow
-$33.1M
Cap. Flow
% of AUM
-2.52%
Top 10 Holdings %
Top 10 Hldgs %
65.03%
Holding
329
New
20
Increased
146
Reduced
123
Closed
37
Top Buys
| 1 |
KLA
KLAC
|
$9.71M |
| 2 |
Pinduoduo
PDD
|
$8.56M |
| 3 |
iShares Gold Trust
IAU
|
$3.24M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.14M |
| 5 |
iShares MSCI Global Gold Miners ETF
RING
|
$3.08M |
Top Sells
| 1 |
Grab
GRAB
|
$40.9M |
| 2 |
NVIDIA
NVDA
|
$7.48M |
| 3 |
Microsoft
MSFT
|
$5.75M |
| 4 |
STAAR Surgical
STAA
|
$4.82M |
| 5 |
Sea Limited
SE
|
$3.38M |
Sector Composition
| 1 | Consumer Discretionary | 45.37% |
| 2 | Technology | 25.37% |
| 3 | Communication Services | 8.93% |
| 4 | Healthcare | 6.43% |
| 5 | Real Estate | 6.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Vaxcyte
PCVX
$4.1B
| $429K | 0.03% |
8,416
-418
| -5% | -$21.3K |
|
152
Krystal Biotech
KRYS
$4.31B
| $428K | 0.03% |
3,687
+830
| +29% | +$96.3K |
|
153
American Electric Power
AEP
$58.9B
| $426K | 0.03% |
5,666
+961
| +20% | +$72.3K |
|
154
GE HealthCare
GEHC
$32.7B
| $426K | 0.03% |
6,262
+901
| +17% | +$61.3K |
|
155
BridgeBio Pharma
BBIO
$9.56B
| $424K | 0.03% |
16,095
-11,821
| -42% | -$311K |
|
156
Roivant Sciences
ROIV
$8.46B
| $424K | 0.03% |
36,291
-2,434
| -6% | -$28.4K |
|
157
Ross Stores
ROST
$49.5B
| $423K | 0.03% |
3,749
+548
| +17% | +$61.8K |
|
158
Beam Therapeutics
BEAM
$1.65B
| $420K | 0.03% |
17,470
+3,603
| +26% | +$86.6K |
|
159
Workday
WDAY
$61.1B
| $420K | 0.03% |
1,953
+414
| +27% | +$89K |
|
|
KRTX
160
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $420K | 0.03% |
2,482
+519
| +26% | +$87.8K |
|
161
Arista Networks
ANET
$171B
| $419K | 0.03% |
2,277
-164
| -7% | -$30.2K |
|
162
Apellis Pharmaceuticals
APLS
$3.56B
| $418K | 0.03% |
10,998
+6,035
| +122% | +$229K |
|
163
CRISPR Therapeutics
CRSP
$4.79B
| $416K | 0.03% |
9,157
+1,863
| +26% | +$84.6K |
|
164
Exelon
EXC
$43.8B
| $414K | 0.03% |
10,944
+1,640
| +18% | +$62K |
|
165
Motorola Solutions
MSI
$79.8B
| $414K | 0.03% |
1,519
-120
| -7% | -$32.7K |
|
166
Arrowhead Research
ARWR
$3.55B
| $411K | 0.03% |
15,293
+2,647
| +21% | +$71.1K |
|
167
Alnylam Pharmaceuticals
ALNY
$58.6B
| $402K | 0.03% |
2,271
-70
| -3% | -$12.4K |
|
168
Exact Sciences
EXAS
$9.09B
| $398K | 0.03% |
5,838
+751
| +15% | +$51.2K |
|
169
Danaher
DHR
$146B
| $396K | 0.03% |
1,595
+86
| +6% | +$21.4K |
|
170
Baker Hughes
BKR
$44.7B
| $392K | 0.03% |
11,107
+1,636
| +17% | +$57.7K |
|
171
Prothena Corp
PRTA
$445M
| $389K | 0.03% |
8,059
+1,632
| +25% | +$78.8K |
|
172
Constellation Energy
CEG
$96B
| $386K | 0.03% |
3,537
+491
| +16% | +$53.6K |
|
173
Intellia Therapeutics
NTLA
$1.22B
| $382K | 0.03% |
12,075
+1,745
| +17% | +$55.2K |
|
174
Pfizer
PFE
$142B
| $378K | 0.03% |
11,408
-421
| -4% | -$14K |
|
175
Verisk Analytics
VRSK
$37B
| $377K | 0.03% |
1,596
+241
| +18% | +$56.9K |
|